We're talking about patent term extension in the pharmaceutical context here so I'm not sure if your remarks before about extension not leading to R and D.... That wouldn't surprise me at all in most other industries where patents don't play as big a role. That could be part of the answer. If patent term extension isn't a good idea across the board, it's really pharmaceuticals where the issue is.
To clarify on the free-riding issue, I agree in many respects that we have a very strong system. I take the point that we have to look at it as a whole. I would be worried that the patent term extension debate shouldn't turn on the idea that we'll get the benefits anyway. If we have a principled objection that says that we don't have patent term extension but we have all these other protections that are just as good as a package and we're doing our bit, that's a fair point. I'm not sure it's correct, but it's a reasonable argument.